Skip to main content
SpringerLink
Log in

An Understanding of Different Mechanisms Leading to Neurodegenerative Diseases

  • Living reference work entry
  • First Online:
Handbook of Neurodegenerative Disorders

  • 82 Accesses

Abstract

The prevalence of neurodegenerative disorders is rapidly increasing causing high morbidity and cognitive deterioration in the elder population. Therefore, it is crucial to find sensitive biomarkers and novel therapeutic approaches to stop these deadly diseases. This chapter will cover the current diagnosis, treatment options, and means of prevention for some neurodegenerative disorders with motor involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Abu-Rumeileh S, Parchi P (2021) Cerebrospinal fluid and blood neurofilament light chain protein in prion disease and other rapidly progressive dementias: current state of the art. Frontiers in Neuroscience 15:153. https://doi.org/10.3389/fnins.2021.648743

  • Abu-Rumeileh S, Redaelli V, Baiardi S, Mackenzie G, Windl O, Ritchie DL, Didato G, Hernandez-Vara J, Rossi M, Capellari S, Imperiale D, Rizzone MG, Belotti A, Sorbi S, Rozemuller AJM, Cortelli P, Gelpi E, Will RG, Zerr I, … Parchi P (2018) Sporadic fatal insomnia in Europe: phenotypic features and diagnostic challenges. Annals of Neurology 84(3):347–360. https://doi.org/10.1002/ana.25300

  • Agarwal S, Highton-Williamson E, Caga J, Matamala JM, Dharmadasa T, Howells J, Zoing MC, Shibuya K, Geevasinga N, Vucic S, Hodges JR, Ahmed RM, Kiernan MC (2018) Primary lateral sclerosis and the amyotrophic lateral sclerosis–frontotemporal dementia spectrum. Journal of Neurology 265(8):1819–1828. https://doi.org/10.1007/s00415-018-8917-5

  • Ahmed Z, Josephs KA, Gonzalez J, DelleDonne A, Dickson DW (2008) Clinical and neuropathologic features of progressive supranuclear palsy with severe pallidonigro-luysial degeneration and axonal dystrophy. Brain: A Journal of Neurology 131(Pt 2):460–472. https://doi.org/10.1093/brain/awm301

  • Ahn JH, Kim M, Kim JS, Youn J, Jang W, Oh E, Lee PH, Koh S-B, Ahn T-B, Cho JW (2019) Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson’s syndrome. Parkinsonism & Related Disorders 66:80–86. https://doi.org/10.1016/j.parkreldis.2019.07.009

  • Aizpurua M, Selvackadunco S, Yull H, Kipps CM, Ironside JW, Bodi I (2019) Variably protease-sensitive prionopathy mimicking frontotemporal dementia. Neuropathology 39(2):135–140. https://doi.org/10.1111/neup.12538

  • Akizuki M, Yamashita H, Uemura K, Maruyama H, Kawakami H, Ito H, Takahashi R (2013) Optineurin suppression causes neuronal cell death via NF-κB pathway. Journal of Neurochemistry 126(6):699–704. https://doi.org/10.1111/jnc.12326

  • Al-Bachari S, Parkes LM, Vidyasagar R, Hanby MF, Tharaken V, Leroi I, Emsley HCA (2014) Arterial spin labeling reveals prolonged arterial arrival time in idiopathic Parkinson’s disease. NeuroImage Clin 6:1–8. https://doi.org/10.1016/j.nicl.2014.07.014

    Article  PubMed  PubMed Central  Google Scholar 

  • Ali F, Josephs KA (2018) Corticobasal degeneration: key emerging issues. J Neurol 265(2):439–445. https://doi.org/10.1007/s00415-017-8644-3

    Article  CAS  PubMed  Google Scholar 

  • Aluri KC, Salisbury JP, Prehn JHM, Agar JN (2020) Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration. Scientific Reports 10(1):3715. https://doi.org/10.1038/s41598-020-60431-6

  • Andersen LK, Knak KL, Witting N, Vissing J (2016) Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. Neurology 86(5):442–445. https://doi.org/10.1212/WNL.0000000000002332

  • Ando S, Kanazawa M, Onodera O (2020) Progressive supranuclear palsy with predominant cerebellar ataxia. Journal of Movement Disorders 13(1):20–26. https://doi.org/10.14802/jmd.19061

  • Arellano-Anaya ZE, Huor A, Leblanc P, Lehmann S, Provansal M, Raposo G, Andréoletti O, Vilette D (2015) Prion strains are differentially released through the exosomal pathway. Cellular and Molecular Life Sciences: CMLS 72(6):1185–1196. https://doi.org/10.1007/s00018-014-1735-8

  • Arnold WD, Kassar D, Kissel JT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51(2):157–167. https://doi.org/10.1002/mus.24497

    Article  CAS  PubMed  Google Scholar 

  • Baek MS, Lee MJ, Kim H-K, Lyoo CH (2021) The temporal trajectory of biofluid markers in Parkinson’s disease. Sci Rep 11(1):14820. https://doi.org/10.1038/s41598-021-94345-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baiardi S, Rossi M, Capellari S, Parchi P (2019) Recent advances in the histomolecular pathology of human prion disease. Brain Pathology 29(2):278–300. https://doi.org/10.1111/bpa.12695

  • Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27–42. https://doi.org/10.1111/ene.14108

    Article  CAS  PubMed  Google Scholar 

  • Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers 1(1):1–21. https://doi.org/10.1038/nrdp.2015.5

    Article  Google Scholar 

  • Bell LC, Fuentes AE, Healey DR, Chao R, Bakkar N, Sirianni RW, Medina DX, Bowser RP, Ladha SS, Semmineh NB, Stokes AM, Quarles CC (2021) Longitudinal evaluation of myofiber microstructural changes in a preclinical ALS model using the transverse relaxivity at tracer equilibrium (TRATE): A preliminary study. Magnetic Resonance Imaging. https://doi.org/10.1016/j.mri.2021.10.036

  • Bento CF, Ashkenazi A, Jimenez-Sanchez M, Rubinsztein DC (2016) The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun 7(1):11803. https://doi.org/10.1038/ncomms11803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bilder RM, Volavka J, Lachman HM, Grace AA (2004) The catechol-O-methyltransferase polymorphism: relations to the tonic–phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29(11):1943–1961. https://doi.org/10.1038/sj.npp.1300542

    Article  CAS  PubMed  Google Scholar 

  • Blandini F, Armentero M-T (2014) Dopamine receptor agonists for Parkinson’s disease. Expert Opin Investig Drugs 23(3):387–410. https://doi.org/10.1517/13543784.2014.869209

    Article  CAS  PubMed  Google Scholar 

  • Bohnen NI, Müller MLTM, Frey KA (2017) Molecular imaging and updated diagnostic criteria in Lewy body dementias. Curr Neurol Neurosci Rep 17(10):73. https://doi.org/10.1007/s11910-017-0789-z

    Article  PubMed  PubMed Central  Google Scholar 

  • Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M (2008) EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain J Neurol 131(Pt 3):690–705. https://doi.org/10.1093/brain/awm322

    Article  Google Scholar 

  • Bond CS, Fox AH (2009) Paraspeckles: nuclear bodies built on long noncoding RNA. The Journal of Cell Biology 186(5):637–644. https://doi.org/10.1083/jcb.200906113

  • Borsche M, König IR, Delcambre S, Petrucci S, Balck A, Brüggemann N, Zimprich A, Wasner K, Pereira SL, Avenali M, Deuschle C, Badanjak K, Ghelfi J, Gasser T, Kasten M, Rosenstiel P, Lohmann K, Brockmann K, Valente EM, … Klein C (2020) Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain 143(10):3041–3051. https://doi.org/10.1093/brain/awaa246

  • Breza M, Koutsis G (2019) Kennedy’s disease (spinal and bulbar muscular atrophy): A clinically oriented review of a rare disease. Journal of Neurology 266(3):565–573. https://doi.org/10.1007/s00415-018-8968-7

  • Calvani R, Picca A, Landi G, Marini F, Biancolillo A, Coelho-Junior HJ, Gervasoni J, Persichilli S, Primiano A, Arcidiacono A, Urbani A, Bossola M, Bentivoglio AR, Cesari M, Bernabei R, Monaco MRL, Marzetti E (2020) A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson’s disease in older people: an EXosomes in Parkinson Disease (EXPAND) ancillary study. Gero Sci 42(5):1323–1334. https://doi.org/10.1007/s11357-020-00192-2

    Article  CAS  Google Scholar 

  • Capellari S, Baiardi S, Rinaldi R, Bartoletti-Stella A, Graziano C, Piras S, Calandra-Buonaura G, D’Angelo R, Terziotti C, Lodi R, Donadio V, Pironi L, Cortelli P, Parchi P (2018) Two novel PRNP truncating mutations broaden the spectrum of prion amyloidosis. Annals of Clinical and Translational Neurology 5(6):777–783. https://doi.org/10.1002/acn3.568

  • Cécile H, Léguillier T, Lebouteux M, Philippe BJ (2021) Subcutaneous apomorphine in the treatment of progressive supranuclear palsy and corticobasal syndrome: a preliminary study of 7 cases. Parkinsonism Relat Disord 95:98–99. https://doi.org/10.1016/j.parkreldis.2021.11.026

    Article  CAS  Google Scholar 

  • Chaytow H, Huang Y-T, Gillingwater TH, Faller KME (2018) The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 75(21):3877–3894. https://doi.org/10.1007/s00018-018-2849-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen H-J, Zhan C, Cai L-M, Lin J-H, Zhou M-X, Zou Z-Y, Yao X-F, Lin Y-J (2021) White matter microstructural impairments in amyotrophic lateral sclerosis: A mean apparent propagator MRI study. NeuroImage: Clinical 32:102863. https://doi.org/10.1016/j.nicl.2021.102863

  • Chew S, Atassi N (2019) Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Frontiers in Neurology 10:135. https://doi.org/10.3389/fneur.2019.00135

  • Chiang S, Kalinowski DS, Dharmasivam M, Braidy N, Richardson DR, Huang MLH (2020) The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich’s ataxia. Pharmacological Research 155:104680. https://doi.org/10.1016/j.phrs.2020.104680

  • Chrobak A, Dudek A, Wnuk M, Łysiak Z, Siwek M, Adamek D, Świerkosz A, Dudek D (2016) Brain biopsy in the diagnosis of Creutzfeldt-Jakob disease with a history of prodromal psychiatric symptoms and catatonic behavior. Archives of Psychiatry and Psychotherapy 18(2). https://doi.org/10.12740/APP/63511

  • Clift K, Guthrie K, Klee EW, Boczek N, Cousin M, Blackburn P, Atwal P (2016) Familial creutzfeldt-jakob disease: case report and role of genetic counseling in post mortem testing. Prion 10(6):502–506. https://doi.org/10.1080/19336896.2016.1254858

  • Cohen OS, Chapman J, Korczyn AD, Nitsan Z, Appel S, Kahana E, Rosenmann H, Hoffmann C (2019) Disease duration in E200K familial Creutzfeldt–Jakob disease is correlated with clinical, radiological, and laboratory variables. Journal of Neural Transmission 126(5):607–611. https://doi.org/10.1007/s00702-018-1958-1

  • Colloby SJ, McParland S, O’Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain J Neurol 135(Pt 9):2798–2808. https://doi.org/10.1093/brain/aws211

    Article  Google Scholar 

  • Contiliani DF, Ribeiro Y de A, de Moraes VN, Pereira TC (2021) MicroRNAs in prion diseases—from molecular mechanisms to insights in translational medicine. Cells 10(7):Article 7. https://doi.org/10.3390/cells10071620

  • Cook A, Giunti P (2017) Friedreich’s ataxia: Clinical features, pathogenesis and management. British Medical Bulletin 124(1):19–30. https://doi.org/10.1093/bmb/ldx034

  • Coon EA, Whitwell JL, Jack Jr. CR, Josephs KA (2012) Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. Movement Disorders 27(7):903–906. https://doi.org/10.1002/mds.24990

  • Cornelius JR, Boes CJ, Ghearing G, Leavitt JA, Kumar N (2009) Visual symptoms in the heidenhain variant of Creutzfeldt-Jakob disease. Journal of Neuroimaging 19(3):283–287. https://doi.org/10.1111/j.1552-6569.2008.00294.x

  • Cotticelli MG, Xia S, Lin D, Lee T, Terrab L, Wipf P, Huryn DM, Wilson RB (2019) Ferroptosis as a novel therapeutic target for Friedreich’s Ataxia. Journal of Pharmacology and Experimental Therapeutics 369(1):47–54. https://doi.org/10.1124/jpet.118.252759

  • Cox PA, Sacks OW (2002) Cycad neurotoxins, consumption of flying foxes, and ALSPDC disease in Guam. Neurology 58(6):956–959. https://doi.org/10.1212/WNL.58.6.956

  • Daube JR (2000) Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle & Nerve 23(10):1488–1502. https://doi.org/10.1002/1097-4598(200010)23:10<1488::aid-mus4>3.0.co;2-e

  • Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144. https://doi.org/10.1016/j.freeradbiomed.2013.01.018

    Article  CAS  PubMed  Google Scholar 

  • Diack AB, Head MW, McCutcheon S, Boyle A, Knight R, Ironside JW, Manson JC, Will RG (2014) Variant CJD. Prion 8(4):286–295. https://doi.org/10.4161/pri.29237

  • Diack AB, Will RG, Manson JC (2017) Public health risks from subclinical variant CJD. PLOS Pathogens 13(11):e1006642. https://doi.org/10.1371/journal.ppat.1006642

  • Dutta D, Chandra G, Mohanakumar KP (2020) The light at the end of the tunnel gets vivid for spinal muscular atrophy. Journal of Neurochemistry 153(5):545–548. https://doi.org/10.1111/jnc.14976

  • Eisen A (2001) Clinical electrophysiology of the upper and lower motor neuron in amyotrophic lateral sclerosis. Seminars in Neurology 21(2):141–154. https://doi.org/10.1055/s-2001-15261

  • Eisen A, Swash M (2001) Clinical neurophysiology of ALS. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology 112(12):2190–2201. https://doi.org/10.1016/s1388-2457(01)00692-7

  • El-Fawal HAN (2014) Neuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunity. Autoimmune Dis 2014(2090-0422):1–12. https://doi.org/10.1155/2014/340875

    Article  CAS  Google Scholar 

  • Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS (2019) Emerging therapies in Parkinson disease – repurposed drugs and new approaches. Nat Rev Neurol 15(4):204–223. https://doi.org/10.1038/s41582-019-0155-7

    Article  PubMed  PubMed Central  Google Scholar 

  • Ellis CM, Suckling J, Amaro E, Bullmore ET, Simmons A, Williams SC, Leigh PN (2001) Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 57(9):1571–1578. https://doi.org/10.1212/wnl.57.9.1571

  • Emamzadeh FN, Surguchov A (2018) Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci 12:612. https://doi.org/10.3389/fnins.2018.00612

    Article  PubMed  PubMed Central  Google Scholar 

  • Emmady PD, Bodle J (2021) Werdnig Hoffmann disease. In: StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK558933/

  • Endo H, Shimada H, Sahara N, Ono M, Koga S, Kitamura S, Niwa F, Hirano S, Kimura Y, Ichise M, Shinotoh H, Zhang MR, Kuwabara S, Dickson DW, Toda T, Suhara T, Higuchi M (2019) In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Movement Disorders 34(5):744–754. https://doi.org/10.1002/mds.27643

  • Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB (2007) How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales. Journal of Neurology, Neurosurgery, and Psychiatry 78(4):411–413. https://doi.org/10.1136/jnnp.2006.096008

  • Fang JY, Tolleson C (2017) The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments. Neuropsychiatr Dis Treat 13:723–732. https://doi.org/10.2147/NDT.S113998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Farotti L, Paolini Paoletti F, Simoni S, Parnetti L (2020) Unraveling pathophysiological mechanisms of Parkinson’s disease: contribution of CSF biomarkers. Biomark Insights 15:1177271920964077. https://doi.org/10.1177/1177271920964077

    Article  PubMed  PubMed Central  Google Scholar 

  • Finsterer J, Scorza FA (2019) Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy’s disease). Clinical Neurology and Neurosurgery 184:105426. https://doi.org/10.1016/j.clineuro.2019.105426

  • Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. J Mov Disord Soc 26(Suppl 3):S2–S41. https://doi.org/10.1002/mds.23829

    Article  Google Scholar 

  • Frank S (2010) Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 6:657–665. https://doi.org/10.2147/NDT.S6430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frau-Méndez MA, Fernández-Vega I, Ansoleaga B, Blanco Tech R, Carmona Tech M, Antonio del Rio J, Zerr I, Llorens F, José Zarranz J, Ferrer I (2017) Fatal familial insomnia: Mitochondrial and protein synthesis machinery decline in the mediodorsal thalamus. Brain Pathology 27(1):95–106. https://doi.org/10.1111/bpa.12408

  • Frempong B, Wilson RB, Schadt K, Lynch DR (2021) The role of serum levels of neurofilament light (NfL) chain as a biomarker in Friedreich Ataxia. Frontiers in Neuroscience 15:173. https://doi.org/10.3389/fnins.2021.653241

  • Gaetani L, Blennow K, Calabresi P, Filippo MD, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry 90(8):870–881. https://doi.org/10.1136/jnnp-2018-320106

  • Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, … Riboli E (2019) Exploring causality of the association between smoking and Parkinson’s disease. Int J Epidemiol, 48(3):912–925. https://doi.org/10.1093/ije/dyy230

  • Gautier CA, Erpapazoglou Z, Mouton-Liger F, Muriel MP, Cormier F, Bigou S, Duffaure S, Girard M, Foret B, Iannielli A, Broccoli V, Dalle C, Bohl D, Michel PP, Corvol J-C, Brice A, Corti O (2016) The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations. Hum Mol Genet 25(14):2972–2984. https://doi.org/10.1093/hmg/ddw148

    Article  CAS  PubMed  Google Scholar 

  • Gerdes H-H (2009) Prions tunnel between cells. Nat Cell Biol 11(3):235–236. https://doi.org/10.1038/ncb0309-235

    Article  CAS  PubMed  Google Scholar 

  • Gerez JA, Riek R (2020) Neurodegenerative diseases distinguished through proteinstructure analysis. Nature 578(7794):223–224. https://doi.org/10.1038/d41586-020-00131-3

  • Ghetti B, Tagliavini F, Takao M, Bugiani O, Piccardo P (2003) Hereditary prion protein amyloidoses. Clinics in Laboratory Medicine 23(1):65–85, viii. https://doi.org/10.1016/s0272-2712(02)00064-1

  • Golbe LI (2014) Progressive supranuclear palsy. Seminars in Neurology 34(2):151–159. https://doi.org/10.1055/s-0034-1381736

  • Gómez-Garre P, Jesús S, Carrillo F, Cáceres-Redondo MT, Huertas-Fernández I, Bernal-Bernal I, Bonilla-Toribio M, Vargas-González L, Carballo M, Mir P (2014) Systematic mutational analysis of FBXO7 in a Parkinson’s disease population from southern Spain. Neurobiol Aging 35(3):727.e5–727.e7. https://doi.org/10.1016/j.neurobiolaging.2013.09.011

    Article  CAS  PubMed  Google Scholar 

  • Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH (2016) PET radioligands reveal the basis of dementia in Parkinson’s disease and dementia with Lewy bodies. Neurodegener Dis 16(1–2):118–124. https://doi.org/10.1159/000441421

    Article  CAS  PubMed  Google Scholar 

  • Goncharova PS, Davydova TK, Popova TE, Novitsky MA, Petrova MM, Gavrilyuk OA, Al-Zamil M, Zhukova NG, Nasyrova RF, Shnayder NA (2021) Nutrient effects on motor neurons and the risk of amyotrophic lateral sclerosis. Nutrients 13(11):Article 11. https://doi.org/10.3390/nu13113804

  • Green AJE (2019) RT-QuIC: a new test for sporadic CJD. Practical Neurology 19(1):49–55. https://doi.org/10.1136/practneurol-2018-001935

  • Greensmith L, Pradat PF, Sorarù G, Pennuto M (2019) 241st ENMC international workshop: Towards a European unifying lab for Kennedy’s disease. 15–17th February, 2019 Hoofddorp, The Netherlands. Neuromuscular Disorders 29(9):716–724. https://doi.org/10.1016/j.nmd.2019.07.008

  • Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Meissner WG, Nilsson C, Piot I, Compta Y, Rowe JB, … Group for the MDS-EPS (2020) Clinical conditions “Suggestive of Progressive Supranuclear Palsy”–Diagnostic Performance. Movement Disorders 35(12):2301–2313. https://doi.org/10.1002/mds.28263

  • Gu M, Kong H-H (2021) Improvement in fine manual dexterity in children with spinal muscular atrophy type 2 after nusinersen injection: a case series. Child Aust 8(11):1039. https://doi.org/10.3390/children8111039

    Article  Google Scholar 

  • Guillot-Sestier M-V, Sunyach C, Druon C, Scarzello S, Checler F (2009) The α-Secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. The Journal of Biological Chemistry 284(51):35973–35986. https://doi.org/10.1074/jbc.M109.051086

  • Halievski K, Xu Y, Haddad YW, Tang YP, Yamada S, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL (2020) Muscle BDNF improves synaptic and contractile muscle strength in Kennedy’s disease mice in a muscle-type specific manner. The Journal of Physiology 598(13):2719–2739. https://doi.org/10.1113/JP279208

  • Hassan AA, Elkins J, Hassan HY (2021) Case report: stem cell therapy in amyotrophic lateral sclerosis (10:1080). F1000Research. https://doi.org/10.12688/f1000research.73967.1

  • Hebron ML, Lonskaya I, Moussa CE-H (2013) Nilotinib reverses the loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models. Hum Mol Genet 22(16):3315–3328. https://doi.org/10.1093/hmg/ddt192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hepkaya E, Kilinc AA, Ülkersoy İ, Baskan AK, Arslan H, Meral Ö, Dilek TD, Guler S, Saltık S, Cokugras H (2021) The effects of nusinersen treatment on respiratuar status of children with spinal muscular atrophy. Pediatr Int 64(1):e15310. https://doi.org/10.22541/au16369981779769760/v1

    Article  Google Scholar 

  • Hermann P, Appleby B, Brandel J-P, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P, Pocchiari M, Satoh K, Zanusso G, Zerr I (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. The Lancet Neurology 20(3):235–246. https://doi.org/10.1016/S1474-4422(20)30477-4

  • Hirsch EC, Jenner P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Disord 28(1):24–30. https://doi.org/10.1002/mds.25032

    Article  CAS  PubMed  Google Scholar 

  • Hong DP, Fink AL, Uversky VN (2009) Smoking and Parkinson’s disease: does nicotine affect α-synuclein fibrillation? Biochim Biophys Acta Proteins Proteom 1794(2):282–290. https://doi.org/10.1016/j.bbapap.2008.09.026

    Article  CAS  Google Scholar 

  • Hong JY, Yun HJ, Sunwoo MK, Ham JH, Lee J-M, Sohn YH, Lee PH (2015) Comparison of regional brain atrophy and cognitive impairment between pure akinesia with gait freezing and Richardson’s syndrome. Frontiers in Aging Neuroscience 0. https://doi.org/10.3389/fnagi.2015.00180

  • Houston F, Andréoletti O (2019) Animal prion diseases: The risks to human health. Brain Pathology 29(2):248–262. https://doi.org/10.1111/bpa.12696

  • Hui CK, Dedkova EN, Montgomery C, Cortopassi G (2020) Dimethyl fumarate dosedependently increases mitochondrial gene expression and function in muscle and brain of Friedreich’s ataxia model mice. Human Molecular Genetics 29(24):3954–3965. https://doi.org/10.1093/hmg/ddaa282

  • Hutchens JA, Johnson TR, Payne RM (2021) Myocardial perfusion reserve in children with Friedreich Ataxia. Pediatric Cardiology. https://doi.org/10.1007/s00246-021-02675-1

  • Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, Marselli L, Marchetti P, Jonas J-C, Eizirik DL, Pandolfo M, Cnop M (2015) Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich’s ataxia. Human Molecular Genetics 24(8):2274–2286. https://doi.org/10.1093/hmg/ddu745

  • Iijima M, Okuma Y, Suzuki K, Yoshii F, Nogawa S, Osada T, Hirata K, Kitagawa K, Hattori N (2021) Associations between probable REM sleep behavior disorder, olfactory disturbance, and clinical symptoms in Parkinson’s disease: a multicenter cross-sectional study. PLoS One 16(2):e0247443. https://doi.org/10.1371/journal.pone.0247443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ishizuchi K, Takizawa T, Tezuka T, Takahata K, Seki M, Tabuchi H, Ueda R, Kubota M, Mimura M, Nakahara J, Ito D (2021) A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [18F]PM-PBB3 tau PET. Journal of the Neurological Sciences 425:117440. https://doi.org/10.1016/j.jns.2021.117440

  • Jansen C, Parchi P, Capellari S, Vermeij AJ, Corrado P, Baas F, Strammiello R, van Gool WA, van Swieten JC, Rozemuller AJM (2010) Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathologica 119(2):189–197. https://doi.org/10.1007/s00401-009-0609-x

  • Jellinger KA, Korczyn AD (2018) Are dementia with Lewy body and Parkinson’s disease dementia the same disease? BMC Med 16(1):1–1. https://doi.org/10.1186/s12916-018-1016-8

    Article  CAS  Google Scholar 

  • Jo M, Lee S, Jeon Y-M, Kim S, Kwon Y, Kim H-J (2020) The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies. Experimental & Molecular Medicine 52(10):1652–1662. https://doi.org/10.1038/s12276-020-00513-7

  • Johnson J, Mercado-Ayón E, Clark E, Lynch D, Lin H (2021) Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia. Pharmacology Research & Perspectives 9(3):e00755. https://doi.org/10.1002/prp2.755

  • Joseph S, Schulz JB, Stegmüller J (2018) Mechanistic contributions of FBXO7 to Parkinson disease. J Neurochem 144(2):118–127. https://doi.org/10.1111/jnc.14253

    Article  CAS  PubMed  Google Scholar 

  • Kalra S (2019) Magnetic resonance spectroscopy in ALS. Frontiers in Neurology 10:482. https://doi.org/10.3389/fneur.2019.00482

  • Kamelgarn M, Chen J, Kuang L, Jin H, Kasarskis EJ, Zhu H (2018) ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proceedings of the National Academy of Sciences 115(51):E11904–E11913. https://doi.org/10.1073/pnas.1810413115

  • Kamienieva I, Duszyński J, Szczepanowska J (2021) Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease. Transl Neurodegener 10(1):5. https://doi.org/10.1186/s40035-020-00229-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kargbo RB (2019) Approaches for prevention and treatment of neurodegenerative diseases: ALS and Alzheimer’s. ACS Medicinal Chemistry Letters 10(12):1588–1589. https://doi.org/10.1021/acsmedchemlett.9b00504

  • Kargbo RB (2020) PROTAC compounds targeting androgen receptor for cancer therapeutics: prostate cancer and Kennedy’s disease. ACS Medicinal Chemistry Letters 11(6):1092–1093. https://doi.org/10.1021/acsmedchemlett.0c00236

  • Kargbo RB (2021) Modulating androgen receptor in the therapeutic intervention for prostate cancer and Kennedy’s disease. ACS Medicinal Chemistry Letters 12(5):685–687. https://doi.org/10.1021/acsmedchemlett.1c00177

  • Kariyawasam DST, D’Silva AM, Herbert K, Howells J, Carey K, Kandula T, Farrar MA, Lin CS-Y (2020) Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. J Physiol 600(1):95–109. https://doi.org/10.1113/JP282249

    Article  Google Scholar 

  • Kemp KC, Cerminara N, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook M, Apps R, Scolding NJ, Wilkins A (2017) Cytokine therapy-mediated neuroprotection in a Friedreich’s ataxia mouse model. Annals of Neurology 81(2):212–226. https://doi.org/10.1002/ana.24846

  • Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications 11(1):812. https://doi.org/10.1038/s41467-020-14612-6

  • Kichula EA, Proud CM, Farrar MA, Kwon JM, Saito K, Desguerre I, McMillan HJ (2021) Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve 64(4):413–427. https://doi.org/10.1002/mus.27363

    Article  PubMed  PubMed Central  Google Scholar 

  • Kiernan M (2019) ALS treatment strategies. Journal of the Neurological Sciences 405:51. https://doi.org/10.1016/j.jns.2019.10.143

  • Kiernan M (2021) New criteria for ALS diagnosis. Journal of the Neurological Sciences 429:117997. https://doi.org/10.1016/j.jns.2021.117997

  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. The Lancet 377(9769):942–955. https://doi.org/10.1016/S0140-6736(10)61156-7

  • Kim H, Jeon B, Fung VSC (2016) Role of magnetic resonance imaging in the diagnosis of multiple system atrophy. Movement Disorders Clinical Practice 4(1):12–20. https://doi.org/10.1002/mdc3.12404

  • Kim YJ, Jeon J, Shin J, Kim NY, Hong JH, Oh J-M, Hong S, Kim YJ, Kim Y-E, Kang SY, Ma H-I, Lee U, Yoon J (2017) Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson’s disease. Mov Disord 32(8):1211–1220. https://doi.org/10.1002/mds.27019

    Article  CAS  PubMed  Google Scholar 

  • Klickovic U, Zampedri L, Sinclair CDJ, Wastling SJ, Trimmel K, Howard RS, Malaspina A, Sharma N, Sidle K, Emira A, Shah S, Yousry TA, Hanna MG, Greensmith L, Morrow JM, Thornton JS, Fratta P (2019) Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology 93(9):e895–e907. https://doi.org/10.1212/WNL.0000000000008009

  • Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson’s disease – the gut-brain axis and environmental factors. Nat Rev Neurol 11(11):625–636. https://doi.org/10.1038/nrneurol.2015.197

    Article  CAS  PubMed  Google Scholar 

  • Knight R (2006) Creutzfeldt-Jakob disease: a rare cause of dementia in elderly persons. Clinical Infectious Diseases 43(3):340–346. https://doi.org/10.1086/505215

  • Koeppen AH (2013) Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord. Journal of Neurochemistry 126(s1):4–10. https://doi.org/10.1111/jnc.12218

  • Krasnianski A, Kaune J, Jung K, Kretzschmar HA, Zerr I (2014) First symptom and initial diagnosis in sporadic CJD patients in Germany. Journal of Neurology 261(9):1811–1817. https://doi.org/10.1007/s00415-014-7410-z

  • Kurt TD, Bett C, Fernández-Borges N, Joshi-Barr S, Hornemann S, Rülicke T, Castilla J, Wüthrich K, Aguzzi A, Sigurdson CJ (2014) Prion transmission prevented by modifying the β2-α2 loop structure of host PrPC. The Journal of Neuroscience 34(3):1022–1027. https://doi.org/10.1523/JNEUROSCI.4636-13.2014

  • Lai BCL, Marion SA, Teschke K, Tsui JKC (2002) Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord 8(5):297–309. https://doi.org/10.1016/S1353-8020(01)00054-2

    Article  CAS  PubMed  Google Scholar 

  • Lamotte G, Millar Vernetti P (2021) Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: Is this the end of the story? Clinical Autonomic Research. https://doi.org/10.1007/s10286-021-00839-w

  • Lane DJR, Metselaar B, Greenough M, Bush AI, Ayton SJ (2021) Ferroptosis and NRF2: An emerging battlefield in the neurodegeneration of Alzheimer’s disease. Essays in Biochemistry, EBC20210017. https://doi.org/10.1042/EBC20210017

  • Lannuzel A, Höglinger GU, Champy P, Michel PP, Hirsch EC, Ruberg M (2006) Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? In Riederer P, Reichmann H, Youdim MBH, Gerlach M (Eds.), Parkinson’s Disease and Related Disorders (pp. 153–157). Springer. https://doi.org/10.1007/978-3-211-45295-0_24

  • Lauraitis A, Maskeliūnas R, Damaševičius R (2018) ANN and fuzzy logic based model to evaluate Huntington disease symptoms. J Healthc Eng 2018:e4581272. https://doi.org/10.1155/2018/4581272

    Article  Google Scholar 

  • Lavigna G, Masone A, Bouybayoune I, Bertani I, Lucchetti J, Gobbi M, Porcu L, Zordan S, Rigamonti M, Imeri L, Restelli E, Chiesa R (2021) Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiology of Disease 158:105455. https://doi.org/10.1016/j.nbd.2021.105455

  • Lecocq C, Charles P, Azulay J-P, Meissner W, Rai M, N’Guyen K, Péréon Y, Fabre N, Robin E, Courtois S, Guyant-Maréchal L, Zagnoli F, Rudolf G, Renaud M, Sévin-Allouet M, Lesne F, Alaerts N, Goizet C, Calvas P, … Anheim M (2016) Delayed-onset Friedreich’s ataxia revisited. Movement Disorders 31(1):62–69. https://doi.org/10.1002/mds.26382

  • Lee SH, Cho H, Choi JY, Choi YS, Lee JH, Ryu YH, Lee MS, Lyoo CH (2017) [p1–386]: distinct tau accumulation pattern in dementia with Lewy body. Alzheimers Dement 13(7S_Part_8):P414–P414. https://doi.org/10.1016/j.jalz.2017.06.402

    Article  Google Scholar 

  • Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN (2019) Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs 28(11):951–965. https://doi.org/10.1080/13543784.2019.1681398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee BH, Waldrop MA, Connolly AM, Ciafaloni E (2021) Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle & Nerve 64(2):153–155. https://doi.org/10.1002/mus.27261

  • Levin J, Nübling G, Giese A, Janzen A, Oertel W (2021) Neuroprotective treatment of idiopathic, genetic and atypical Parkinson’s disease with alpha-synuclein-Pathology. Der Nervenarzt. https://doi.org/10.1007/s00115-021-01220-y

  • Li J, Cao F, Yin H, Huang Z, Lin Z, Mao N, Sun B, Wang G (2020) Ferroptosis: Past, present and future. Cell Death & Disease 11(2):1–13. https://doi.org/10.1038/s41419-020-2298-2

  • Li W, Fu Y, Halliday GM, Sue CM (2021) PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease. Front Cell Dev Biol 9:1755. https://doi.org/10.3389/fcell.2021.612476

    Article  Google Scholar 

  • Ling H, de Silva R, Massey LA, Courtney R, Hondhamuni G, Bajaj N, Lowe J, Holton JL, Lees A, Revesz T (2014) Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: A cortical variant. Neuropathology and Applied Neurobiology 40(2):149–163. https://doi.org/10.1111/nan.12037

  • Lippai R, Veres-Székely A, Sziksz E, Iwakura Y, Pap D, Rokonay R, Szebeni B, Lotz G, Béres NJ, Cseh Á, Szabó AJ, Vannay Á (2021) Immunomodulatory role of Parkinson’s disease 7 in inflammatory bowel disease. Sci Rep 11(1):14582. https://doi.org/10.1038/s41598-021-93671-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Bai H, Gen S, Zhang H, Wang S, Hua L, Yang X, Zhang S, Li J, Wang Y (2020) Interaction between SNCA gene polymorphisms and T2DM with Parkinson’s disease. Acta Neurol Scand 142(5):443–448. https://doi.org/10.1111/ane.13292

    Article  CAS  PubMed  Google Scholar 

  • López-Mora DA, Camacho V, Pérez-Pérez J, Martínez-Horta S, Fernández A, Sampedro F, Montes A, Lozano-Martínez GA, Gómez-Anson B, Kulisevsky J, Carrió I (2016) Striatal hypometabolism in premanifest and manifest Huntington’s disease patients. Eur J Nucl Med Mol Imaging 43(12):2183–2189. https://doi.org/10.1007/s00259-016-3445-y

    Article  CAS  PubMed  Google Scholar 

  • Lu T, Pan Y, Peng L, Qin F, Sun X, Lu Z, Qiu W (2017) Fatal familial insomnia with abnormal signals on routine MRI: A case report and literature review. BMC Neurology 17(1):104. https://doi.org/10.1186/s12883-017-0886-2

  • Mahajan R (2019) Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever. Int J Appl Basic Med Res 9(3):127–128. https://doi.org/10.4103/ijabmr.ijabmr_190_19

    Article  PubMed  PubMed Central  Google Scholar 

  • Maheshwari A, Fischer M, Gambetti P, Parker A, Ram A, Soto C, Concha-Marambio L, Cohen Y, Belay ED, Maddox RA, Mead S, Goodman C, Kass JS, Schonberger LB, Hussein HM (2015) Recent US case of variant creutzfeldt-jakob disease—global implications. Emerging Infectious Diseases 21(5):750–759. https://doi.org/10.3201/eid2105.142017

  • Mahul-Mellier A-L, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, Leleu M, Knott GW, Lashuel HA (2020) The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci 117(9):4971–4982. https://doi.org/10.1073/pnas.1913904117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malek N (2019) Deep brain stimulation in Parkinson’s disease. Neurol India 67(4):968. https://doi.org/10.4103/0028-3886.266268

    Article  PubMed  Google Scholar 

  • Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A (2015) Creutzfeldt-Jakob disease: Updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurgical Focus 39(5):E2. https://doi.org/10.3171/2015.8.FOCUS15328

  • Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson’s disease. Clin Neuropharmacol 17(Suppl 2):S32–S44

    PubMed  Google Scholar 

  • Marsili L, Colosimo C (2020) The “gunslinger” sign in progressive supranuclear palsy – Richardson variant. Journal of the Neurological Sciences 418:117108. https://doi.org/10.1016/j.jns.2020.117108

  • Marsili L, Suppa A, Berardelli A, Colosimo C (2016) Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism Relat Disord 22:S96–S100. https://doi.org/10.1016/j.parkreldis.2015.09.023

    Article  PubMed  Google Scholar 

  • Mastrangelo V, Merli E, Rucker JC, Eggenberger ER, Zee DS, Cortelli P (2021) Neuro-ophthalmological findings in early fatal familial insomnia. Annals of Neurology 89(4):823–827. https://doi.org/10.1002/ana.26008

  • Mays CE, Soto C (2016) The stress of prion disease. Brain Research 1648:553–560. https://doi.org/10.1016/j.brainres.2016.04.009

  • Megelin T, Thomas B, Ferrer X, Ghorayeb I (2017) Fatal familial insomnia: A videopolysomnographic case report. Sleep Medicine 33:165–166. https://doi.org/10.1016/j.sleep.2017.02.015

  • Mehra S, Sahay S, Maji SK (2019) α-Synuclein misfolding and aggregation: implications in Parkinson’s disease pathogenesis. Biochim Biophys Acta Proteins Proteom 1867(10):890–908. https://doi.org/10.1016/j.bbapap.2019.03.001

    Article  CAS  PubMed  Google Scholar 

  • Mészáros L, Hoffmann A, Wihan J, Winkler J (2020) Current symptomatic and disease-modifying treatments in multiple system atrophy. International Journal of Molecular Sciences 21(8):Article 8. https://doi.org/10.3390/ijms21082775

  • Meyer M, Lamare F, Asselineau J, Foubert-Samier A., Mazère J, Zanotti-Fregonara P, Rizzo G, Delamarre A, Spampinato U, Rascol O, Pavy-Le Traon A, Tison F, Fernandez P, Sibon I, Meissner WG (2021) Brain 5-HT1A receptor binding in multiple system atrophy: An [18F]-MPPF PET Study. Movement Disorders 36(1):246–251. https://doi.org/10.1002/mds.28295

  • Mirek E, Filip M, Banaszkiewicz K, Rudzińska M, Szymura J, Pasiut S, Stożek J, Szczudlik A (2015) The effects of physiotherapy with PNF concept on gait and balance of patients with Huntington’s disease – pilot study. Neurol Neurochir Pol 49(6):354–357. https://doi.org/10.1016/j.pjnns.2015.09.002

    Article  PubMed  Google Scholar 

  • Montagna P, Gambetti P, Cortelli P, Lugaresi E (2003) Familial and sporadic fatal insomnia. The Lancet. Neurology 2(3):167–176. https://doi.org/10.1016/s1474-4422(03)00323-5

  • Mortezazadeh T, Seyedarabi H, Mahmoudian B, Islamian JP (2021) Imaging modalities in differential diagnosis of Parkinson’s disease: opportunities and challenges. Egypt J Radiol Nucl Med 52(1):79. https://doi.org/10.1186/s43055-021-00454-9

    Article  Google Scholar 

  • Müller T (2015) Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs 75(2):157–174. https://doi.org/10.1007/s40265-014-0343-0

    Article  CAS  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (UK) (2018) Dementia: assessment, management, and support for people living with dementia and their carers. National Institute for Health and Care Excellence (UK). http://www.ncbi.nlm.nih.gov/books/NBK513207/

    Google Scholar 

  • Ng ASL, Tan YJ, Lu Z, Ng EY, Ng SYE, Chia NSY, Setiawan F, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan E-K (2020) Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson’s disease. Aging 12(2):1488–1495. https://doi.org/10.18632/aging.102695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Niccolini F, Wilson H, Hirschbichler S, Yousaf T, Pagano G, Whittington A, Caminiti SP, Erro R, Holton JL, Jaunmuktane Z, Esposito M, Martino D, Abdul A, Passchier J, Rabiner EA, Gunn RN, Bhatia KP, Politis M, for the Alzheimer’s Disease Neuroimaging Initiative (2018) Disease-related patterns of in vivo pathology in Corticobasal syndrome. Eur J Nucl Med Mol Imaging 45(13):2413–2425. https://doi.org/10.1007/s00259-018-4104-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Notari S, Appleby BS, Gambetti P (2018) Variably protease-sensitive prionopathy. Handbook of Clinical Neurology 153:175–190. https://doi.org/10.1016/B978-0-444-63945-5.00010-6

  • Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V (2012) Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurology 12(1):131. https://doi.org/10.1186/1471-2377-12-131

  • O’Bryant SE, Ferman TJ, Zhang F, Hall J, Pedraza O, Wszolek ZK, Como T, Julovich D, Mattevada S, Johnson LA, Edwards M, Hall J, Graff-Radford NR (2019) A proteomic signature for dementia with Lewy bodies. Alzheimers Dement (Amst) 11:270–276. https://doi.org/10.1016/j.dadm.2019.01.006

    Article  PubMed  Google Scholar 

  • Oda H, Ishii K, Terashima A, Shimada K-I, Yamane Y, Kawasaki R, Ohkawa S (2013) Myocardial scintigraphy may predict the conversion to probable dementia with Lewy bodies. Neurology 81(20):1741–1745. https://doi.org/10.1212/01.wnl.0000435553.67953.81

    Article  PubMed  Google Scholar 

  • Ou R, Wei Q, Hou Y, Zhang L, Liu K, Xu X, Gu X, Lin J, Jiang Z, Liu J, Song W, Cao B, Shang H (2020) Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. J Affect Disord 276:1061–1068. https://doi.org/10.1016/j.jad.2020.07.127

    Article  PubMed  Google Scholar 

  • P G, Z D, J Y, X X, M Z, A A, R C, M C, Ma B, D G-R, Ed B, Lb S, K M, C H, Jr B, T M, T W, Dw D, C S, … Wq Z (2008) A novel human disease with abnormal prion protein sensitive to protease. Annals of Neurology 63(6). https://doi.org/10.1002/ana.21420

  • Pagano G, Niccolini F, Politis M (2016) Imaging in Parkinson’s disease. Clin Med 16(4):371–375. https://doi.org/10.7861/clinmedicine.16-4-371

    Article  Google Scholar 

  • Palleis C, Brendel M, Finze A, Weidinger E, Bötzel K, Danek A, Beyer L, Nitschmann A, Kern M, Biechele G, Rauchmann BS, Häckert J, Höllerhage M, Stephens AW, Drzezga A, van Eimeren T, Villemagne VL, Schildan A, Barthel H, … Höglinger GU (2021) Cortical [18F]PI-2620 binding differentiates Corticobasal syndrome subtypes. Mov Disord 36(9):2104–2115. https://doi.org/10.1002/mds.28624

  • Panegyres PK, Stehmann C, Klug GM, Masters CL, Collins S (2021) Prion disease in Indigenous Australians. Internal Medicine Journal 51(7):1101–1105. https://doi.org/10.1111/imj.14835

  • Parmera JB, Coutinho AM, Aranha MR, Studart-Neto A, de Godoi Carneiro C, de Almeida IJ, Fontoura Solla DJ, Ono CR, Barbosa ER, Nitrini R, Buchpiguel CA, Brucki SMD (2021) FDG-PET patterns predict amyloid deposition and clinical profile in Corticobasal syndrome. Mov Disord 36(3):651–661. https://doi.org/10.1002/mds.28373

    Article  CAS  PubMed  Google Scholar 

  • Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour N, Varghese S, El-Agnaf O, Calabresi P (2014) Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson’s disease. Front Aging Neurosci 6:53. https://doi.org/10.3389/fnagi.2014.00053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pedroso JL, Vale TC, Barsottini OG, Oliveira ASB, Espay AJ (2018) Perioral and tongue fasciculations in Kennedy’s disease. Neurological Sciences 39(4):777–779. https://doi.org/10.1007/s10072-017-3170-8

  • Perneczky R, Drzezga A, Boecker H, Förstl H, Kurz A, Häussermann P (2008) Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord 25(6):531–538. https://doi.org/10.1159/000132084

    Article  CAS  PubMed  Google Scholar 

  • Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, … MOVES-PD Investigators (2021) Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson’s disease and a GBA mutation: results from part 1 of the randomized, double-blinded, Placebo-Controlled MOVES-PD trial. J Parkinson’s Dis. https://doi.org/10.3233/JPD-212714

  • Petrillo S, D’Amico J, La Rosa P, Bertini ES, Piemonte F (2019) Targeting NRF2 for the treatment of Friedreich’s Ataxia: A comparison among drugs. International Journal of Molecular Sciences 20(20):5211. https://doi.org/10.3390/ijms20205211

  • Petrov D, Mansfield C, Moussy A, Hermine O (2017) ALS clinical trials review: 20 years of failure. Are We Any Closer to Registering a New Treatment? Frontiers in Aging Neuroscience 9:68. https://doi.org/10.3389/fnagi.2017.00068

  • Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3(1):1–21. https://doi.org/10.1038/nrdp.2017.13

    Article  Google Scholar 

  • Pradat P-F, Bernard E, Corcia P, Couratier P, Jublanc C, Querin G, Morélot Panzini C, Salachas F, Vial C, Wahbi K, Bede P, Desnuelle C, on behalf of the French Kennedy’s Disease Writing Group, Le Forestier N, Echaniz-Laguna A, Sorarù, G, Perez T, Ramos C, Goizet C, Desport JC (2020) The French national protocol for Kennedy’s disease (SBMA): Consensus diagnostic and management recommendations. Orphanet Journal of Rare Diseases 15(1):1–21. https://doi.org/10.1186/s13023-020-01366-z

  • Qi C, Zhang J-T, Zhao W, Xing X-W, Yu S-Y (2020) Sporadic creutzfeldt-jakob disease: A retrospective analysis of 104 cases. European Neurology 83(1):65–72. https://doi.org/10.1159/000507189

  • Querin G, Bede P, Marchand-Pauvert V, Pradat P-F (2018) Biomarkers of spinal and bulbar muscle atrophy (SBMA): A comprehensive review. Frontiers in Neurology 9:844. https://doi.org/10.3389/fneur.2018.00844

  • Raccagni C, Nonnekes J, Bloem BR, Peball M, Boehme C, Seppi K, Wenning GK (2020) Gait and postural disorders in parkinsonism: a clinical approach. J Neurol 267(11):3169–3176. https://doi.org/10.1007/s00415-019-09382-1

    Article  PubMed  Google Scholar 

  • Reich SG, Savitt JM (2019) Parkinson’s disease. Med Clin North Am 103(2):337–350. https://doi.org/10.1016/j.mcna.2018.10.014

    Article  PubMed  Google Scholar 

  • Ritchie DL, Ironside JW (2017) Chapter fourteen–neuropathology of human prion diseases. In Legname G, Vanni S (Eds.), Progress in Molecular Biology and Translational Science (Vol. 150, pp. 319–339). Academic Press. https://doi.org/10.1016/bs.pmbts.2017.06.011

  • Robakis D, Fahn S (2015) Defining the role of the monoamine oxidase-B inhibitors for Parkinson’s disease. CNS Drugs 29(6):433–441. https://doi.org/10.1007/s40263-015-0249-8

    Article  CAS  PubMed  Google Scholar 

  • Rojas P, de Hoz R, Cadena M, Salobrar-García E, Fernández-Albarral JA, López-Cuenca I, Elvira-Hurtado L, Urcelay-Segura JL, Salazar JJ, Ramírez JM, Ramírez AI (2021) Neuro-ophthalmological findings in Friedreich’s Ataxia. Journal of Personalized Medicine 11(8):Article 8. https://doi.org/10.3390/jpm11080708

  • Roncero C, Friedman M, Whittaker K, Popov A, Chertkow H (2021) Administration of 4 mA tDCS to a person with progressive supranuclear palsy leads to improved walking speed. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation 14(6):1563–1565. https://doi.org/10.1016/j.brs.2021.10.390

  • Rosenbohm A, Hirsch S, Volk AE, Grehl T, Grosskreutz J, Hanisch F, Herrmann A, Kollewe K, Kress W, Meyer T, Petri S, Prudlo J, Wessig C, Müller H-P, Dreyhaupt J, Weishaupt J, Kubisch C, Kassubek J, Weydt P, Ludolph AC (2018) The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology 265(5):1026–1036. https://doi.org/10.1007/s00415-018-8790-2

  • Roucou X, Gains M, LeBlanc AC (2004) Neuroprotective functions of prion protein. Journal of Neuroscience Research 75(2):153–161. https://doi.org/10.1002/jnr.10864

  • Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JDF, Brandner S, Hyare H, Mead S, Collinge J (2015) Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 138(11):3386–3399. https://doi.org/10.1093/brain/awv235

  • Rufin SD, Pol S, Wiese M, Vassilev K, Mazevet D (2021) Results of botulinum toxin injections for the treatment of spasticity in patients with primary lateral sclerosis. Toxicon 190:S64–S65. https://doi.org/10.1016/j.toxicon.2020.11.479

  • Rummey C, Corben LA, Delatycki MB, Subramony SH, Bushara K, Gomez CM, Hoyle JC, Yoon G, Ravina B, Mathews KD, Wilmot G, Zesiewicz T, Perlman S, Farmer JM, Lynch DR (2019) Psychometric properties of the Friedreich Ataxia Rating Scale. Neurology Genetics 5(6). https://doi.org/10.1212/NXG.0000000000000371

  • Saal HJ, Heerinckx F, Zawadzki R, Omidvar O, Kilpatrick M, Zesiewicz T (2018) Strong correlations among four measures of disease progression in Friedreich’s ataxia. Movement Disorders 33(6):1021–1022. https://doi.org/10.1002/mds.27351

  • Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411(6839):810–813. https://doi.org/10.1038/35081095

  • Salama M, Shalash A, Magdy A, Makar M, Roushdy T, Elbalkimy M, Elrassas H, Elkafrawy P, Mohamed W, Donia MBA (2018) Tubulin and tau: possible targets for diagnosis of Parkinson’s and Alzheimer’s diseases. PLoS One 13(5):e0196436. https://doi.org/10.1371/journal.pone.0196436

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sánchez-Ruiz de Gordoa J, Erro ME, Vicuña-Urriza J, Zelaya MV, Tellechea P, Acha B, Zueco S, Urdánoz-Casado A, Roldán M, Blanco-Luquin I, Mendioroz M (2020) Microglia-related gene triggering receptor expressed in myeloid cells 2 (TREM2) is upregulated in the substantia nigra of progressive supranuclear palsy. Movement Disorders 35(5):885–890. https://doi.org/10.1002/mds.27992

  • Schirinzi T, Sancesario A, Castelli E, Bertini E, Vasco G (2021) Friedreich ataxia in COVID-19 time: Current impact and future possibilities. Cerebellum & Ataxias 8(1):4. https://doi.org/10.1186/s40673-020-00127-9

  • Schmitt-Ulms G, Legname G, Baldwin MA, Ball HL, Bradon N, Bosque PJ, Crossin KL, Edelman GM, DeArmond SJ, Cohen FE, Prusiner SB (2001) Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. Journal of Molecular Biology 314(5):1209–1225. https://doi.org/10.1006/jmbi.2000.5183

  • Schocke MFH, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK (2002) Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58(4):575–580. https://doi.org/10.1212/WNL.58.4.575

    Article  CAS  PubMed  Google Scholar 

  • Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous Sr MD, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, … Rabinovici GD (2017) 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology 82(4):622–634. https://doi.org/10.1002/ana.25060

  • Schulz-Schaeffer WJ (2010) The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease, and Parkinson’s disease dementia. Acta Neuropathol 120(2):131–143. https://doi.org/10.1007/s00401-010-0711-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schwabova J, Maly T, Laczo J, Zumrova A, Komarek V, Musova Z, Zahalka F (2014) Application of a scale for the assessment and rating of ataxia (SARA) in Friedreich’s ataxia patients according to posturography is limited. Journal of the Neurological Sciences 341(1):64–67. https://doi.org/10.1016/j.jns.2014.04.001

  • Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai A-L, Shirani H, Nilsson KPR, Low PA, Soto C (2020) Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578(7794):273–277. https://doi.org/10.1038/s41586-020-1984-7

  • Shalash A, Salama M, Makar M, Roushdy T, Elrassas HH, Mohamed W, El-Balkimy M, Abou Donia M (2017) Elevated serum α-synuclein autoantibodies in patients with Parkinson’s disease relative to Alzheimer’s disease and controls. Front Neurol 8:720. https://doi.org/10.3389/fneur.2017.00720

    Article  PubMed  PubMed Central  Google Scholar 

  • Shen T, Hu J, Jiang Y, Zhao S, Lin C, Yin X, Yan Y, Pu J, Lai H-Y, Zhang B (2019) Early-onset Parkinson’s disease caused by PLA2G6 compound heterozygous mutation, a case report and literature review. Front Neurol 10:915. https://doi.org/10.3389/fneur.2019.00915

    Article  PubMed  PubMed Central  Google Scholar 

  • Shola-Dare O, Bailess S, Flores CC, Vanderheyden WM, Gerstner JR (2021) Glitazone treatment rescues phenotypic deficits in a Fly model of Gaucher/Parkinson’s disease. Int J Mol Sci 22(23):12740. https://doi.org/10.3390/ijms222312740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sigurdson CJ, Bartz JC, Glatzel M (2019) Cellular and molecular mechanisms of prion disease. Annual Review of Pathology: Mechanisms of Disease 14(1):497–516. https://doi.org/10.1146/annurev-pathmechdis-012418-013109

  • Silajdžić E, Björkqvist M (2018) A critical evaluation of wet biomarkers for Huntington’s disease: current status and ways forward. J Huntington’s Dis 7(2):109–135. https://doi.org/10.3233/JHD-170273

    Article  Google Scholar 

  • Silsby M, Tweedie-Cullen RY, Murray CR, Halliday GM, Hodges JR, Burrell JR (2017) The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias. European Journal of Neurology 24(7):956–965. https://doi.org/10.1111/ene.13314

  • Simonsen AH, Kuiperij B, El-Agnaf OMA, Engelborghs S, Herukka S-K, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M, Mollenhauer B (2016) The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med 10(1):19–34. https://doi.org/10.2217/BMM.14.105

    Article  CAS  PubMed  Google Scholar 

  • Singer MA, Statland JM, Wolfe GI, Barohn RJ (2007) Primary lateral sclerosis. Muscle & Nerve 35(3):291–302. https://doi.org/10.1002/mus.20728

  • Singh UP, Bhat HR (2018) Discovery of 1,3,5-triazine-thiazoles (DDTR-502) as potent A2A antagonist/MAO-B inhibitor for the treatment of Parkinson’s disease. Parkinsonism Relat Disord 46:e39–e40. https://doi.org/10.1016/j.parkreldis.2017.11.129

    Article  Google Scholar 

  • Spindel J, Fletcher A, Smith W, Cavallazzi R (2021) Prion disease: A challenging diagnosis. The University of Louisville Journal of Respiratory Infections 5(1). https://ir.library.louisville.edu/jri/vol5/iss1/29

  • Spinelli EG, Agosta F, Ferraro PM, Querin G, Riva N, Bertolin C, Martinelli I, Lunetta C, Fontana A, Sorarù G, Filippi M (2019) Brain MRI shows white matter sparing in Kennedy’s disease and slow-progressing lower motor neuron disease. Human Brain Mapping 40(10):3102–3112. https://doi.org/10.1002/hbm.24583

  • Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(S1):318–324. https://doi.org/10.1111/jnc.13691

    Article  CAS  PubMed  Google Scholar 

  • Tabaee Damavandi P, Dove MT, Pickersgill RW (2017) A review of drug therapy for sporadic fatal insomnia. Prion 11(5):293–299. https://doi.org/10.1080/19336896.2017.1368937

  • Taguchi T, Ikuno M, Yamakado H, Takahashi R (2020) Animal model for prodromal Parkinson’s disease. Int J Mol Sci 21(6):1961. https://doi.org/10.3390/ijms21061961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ, O’Brien JT (2020) New evidence on the management of Lewy body dementia. The Lancet Neurology 19(2):157–169. https://doi.org/10.1016/S1474-4422(19)30153-X

  • Tesar A, Matej R, Kukal J, Johanidesova S, Rektorova I, Vyhnalek M, Keller J, Eliasova I, Parobkova E, Smetakova M, Musova Z, Rusina R (2019) Clinical variability in P102L Gerstmann–Sträussler–Scheinker Syndrome. Annals of Neurology 86(5):643–652. https://doi.org/10.1002/ana.25579

  • Toth RP, Atkin JD (2018) Dysfunction of optineurin in amyotrophic lateral sclerosis and glaucoma. Frontiers in Immunology 9:1017. https://doi.org/10.3389/fimmu.2018.01017

  • Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grünewald A, Almuammar S, König IR, Lill CM, Lohmann K, Klein C, Marras C (2018) Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33(12):1857–1870. https://doi.org/10.1002/mds.27527

    Article  CAS  PubMed  Google Scholar 

  • Unti E, Mazzucchi S, Calabrese R, Palermo G, Del Prete E, Bonuccelli U, Ceravolo R (2019) Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. Brain Behav 9(6):e01182. https://doi.org/10.1002/brb3.1182

    Article  PubMed  PubMed Central  Google Scholar 

  • van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briedé JJ (2020) Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol 185:101732. https://doi.org/10.1016/j.pneurobio.2019.101732

    Article  PubMed  Google Scholar 

  • van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV, Bridel C, Ferri G-L, Cocco C, Noli B, Worley PF, Xiao M-F, Xu D, Oeckl P, Otto M, van der Flier WM, de Jong FJ, Jimenez CR, Lemstra AW, Teunissen CE (2020) Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener 15(1):36. https://doi.org/10.1186/s13024-020-00388-2

    Article  PubMed  PubMed Central  Google Scholar 

  • Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, Cook SF, Lochmüller H (2017) Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy–A literature review. Orphanet Journal of Rare Diseases 12:1–15. https://doi.org/10.1186/s13023-017-0671-8

  • Villa C, Legato M, Umbach A, Riganti C, Jones R, Martini B, Boido M, Medana C, Facchinetti I, Barni D, Pinto M, Arguello T, Belicchi M, Fagiolari G, Liaci C, Moggio M, Ruffo R, Moraes CT, Monguzzi A, … Torrente Y (2021) Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. Science Translational Medicine 13(607):eabe1633. https://doi.org/10.1126/scitranslmed.abe1633

  • Vucic S, Pamphlett R, Wills EJ, Yiannikas C (2007) Polyglucosan body disease myopathy: An unusual presentation. Muscle & Nerve 35(4):536–539. https://doi.org/10.1002/mus.20720

  • Vyas PM, Tomamichel WJ, Pride PM, Babbey CM, Wang Q, Mercier J, Martin EM, Payne RM (2012) A TAT–Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Human Molecular Genetics 21(6):1230–1247. https://doi.org/10.1093/hmg/ddr554

  • Wang S, Poptani H, Bilello M, Wu X, Woo JH, Elman LB, McCluskey LF, Krejza J, Melhem ER (2006) Diffusion tensor imaging in amyotrophic lateral sclerosis: Volumetric analysis of the corticospinal tract. AJNR. American Journal of Neuroradiology 27(6):1234–1238

    Google Scholar 

  • Watson R, Colloby SJ, Blamire AM, O’Brien JT (2015) Assessment of regional gray matter loss in dementia with Lewy bodies: a surface-based MRI analysis. Am J Geriatr Psychiatry 23(1):38–46. https://doi.org/10.1016/j.jagp.2014.07.005

    Article  PubMed  Google Scholar 

  • Wei X, Roettger Y, Tan B, He Y, Dodel R, Hampel H, Wei G, Haney J, Gu H, Johnstone BH, Liu J, Farlow MR, Du Y (2012) Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. Journal of Biological Chemistry 287(16):12858–12866. https://doi.org/10.1074/jbc.M111.255836

  • Weinstein RA, Rutala WA, Weber DJ (2001) Creutzfeldt-Jakob Disease: Recommendations for disinfection and sterilization. Clinical Infectious Diseases 32(9):1348–1356. https://doi.org/10.1086/319997

  • Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, Knopman DS, Petersen RC, Benarroch EE, Josephs KA, Jack CR (2007) Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain J Neurol 130(Pt 3):708–719. https://doi.org/10.1093/brain/awl388

    Article  Google Scholar 

  • Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ, Ahlskog JE, Knopman DS, Petersen RC, Jack Jr CR, Lowe VJ, Josephs KA (2019) MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Movement Disorders 34(1):105–113. https://doi.org/10.1002/mds.27546

  • Wicks P, Ganesalingham J, Collin C, Prevett M, Leigh NP, Al-Chalabi A (2007) Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 8(3):177–179. https://doi.org/10.1080/17482960701195220

  • Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8(3):270–279. https://doi.org/10.1016/S1474-4422(09)70042-0

    Article  PubMed  Google Scholar 

  • Winhammar JMC, Rowe DB, Henderson RD, Kiernan MC (2005) Assessment of disease progression in motor neuron disease. The Lancet Neurology 4(4):229–238. https://doi.org/10.1016/S1474-4422(05)70042-9

  • Wu J, Chen D, Shi Q, Dong X (2021) Protein amplification technology: New advances in human prion disease diagnosis. Biosafety and Health. https://doi.org/10.1016/j.bsheal.2021.09.003

  • Xu X, Fu Z, Le W (2019) Exercise and Parkinson’s disease. Int Rev Neurobiol 147:45–74. https://doi.org/10.1016/bs.irn.2019.06.003

    Article  CAS  PubMed  Google Scholar 

  • Yamada M (2000) Cerebral amyloid angiopathy: An overview. Neuropathology 20(1):8–22. https://doi.org/10.1046/j.1440-1789.2000.00268.x

  • Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song E-S, Cairns NJ, Kotzbauer PT, Diamond MI (2019) Parkinson’s disease and multiple system atrophy have distinct α-synuclein seed characteristics. Journal of Biological Chemistry 294(3):1045–1058. https://doi.org/10.1074/jbc.RA118.004471

  • Yapijakis C (2017) Huntington Disease: genetics, prevention, and therapy approaches. In: Vlamos P (ed) GeNeDis 2016. Springer International Publishing, pp 55–65. https://doi.org/10.1007/978-3-319-57379-3_6

    Chapter  Google Scholar 

  • Yousaf T, Dervenoulas G, Valkimadi P-E, Politis M (2019) Neuroimaging in Lewy body dementia. J Neurol 266(1):1–26. https://doi.org/10.1007/s00415-018-8892-x

    Article  PubMed  Google Scholar 

  • Zahirovic I, Londos E, Torisson G, Wattmo C (2017) [p4–303]: dementia with Lewy body (dlb) symptoms hidden within the diagnosis ‘dementia not otherwise specified: a cross-sectional study in 40 Swedish nursing homes. Alzheimers Dement 13(7S_Part_29):P1406–P1406. https://doi.org/10.1016/j.jalz.2017.06.2173

    Article  Google Scholar 

  • Zesiewicz T, Heerinckx F, De Jager R, Omidvar O, Kilpatrick M, Shaw J, Shchepinov MS (2018) Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich’s ataxia. Movement Disorders 33(6):1000–1005. https://doi.org/10.1002/mds.27353

  • Zhang Q, Kim Y, Narayanan N (2015) Disease-modifying therapeutic directions for Lewy-body dementias. Front Neurosci 9:293. https://doi.org/10.3389/fnins.2015.00293

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang L, Wang J, Wang J, Yang B, He Q, Weng Q (2020) Role of DJ-1 in immune and inflammatory diseases. Front Immunol 11:994. https://doi.org/10.3389/fimmu.2020.00994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2021) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Movement Disorders n/a(n/a). https://doi.org/10.1002/mds.28847

  • Zhao Y-W, Pan H-X, Liu Z, Wang Y, Zeng Q, Fang Z-H, Luo T-F, Xu K, Wang Z, Zhou X, He R, Li B, Zhao G, Xu Q, Sun Q-Y, Yan X-X, Tan J-Q, Li J-C, Guo J-F, Tang B-S (2021) The association between lysosomal storage disorder genes and Parkinson’s disease: a large cohort study in Chinese mainland population. Front Aging Neurosci 13:749109. https://doi.org/10.3389/fnagi.2021.749109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, Pratt DA (2017) On the mechanism of cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Central Science 3(3):232–243. https://doi.org/10.1021/acscentsci.7b00028

  • Zubair AS, Raymond M, Patwa HS (2021) Utility of intrathecal baclofen pump in primary lateral sclerosis. Journal of the Neurological Sciences 420:117227. https://doi.org/10.1016/j.jns.2020.117227

Download references

Author information

Authors and Affiliations

  1. Institute of Global Health and Human Ecology, School of Sciences and Engineering, The American University of Cairo, New Cairo, Egypt

    Diana G. Sami & Mohamed Salama

Authors
  1. Diana G. Sami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana G. Sami .

Editor information

Editors and Affiliations

  1. Coll of Agricultural & Marine Sciences, Sultan Qaboos University, Muscat, Oman

    Essa Mohamed

Section Editor information

  1. Institute of Global Health and Human Ecology, School of Sciences & Engineering, The American University in Cairo, New Cairo, Egypt

    Mohamed Salama

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Sami, D.G., Salama, M. (2023). An Understanding of Different Mechanisms Leading to Neurodegenerative Diseases. In: Mohamed, E. (eds) Handbook of Neurodegenerative Disorders . Springer, Singapore. https://doi.org/10.1007/978-981-19-3949-5_10-1

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-3949-5_10-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-3949-5

  • Online ISBN: 978-981-19-3949-5

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation